Senzime is on a mission to safeguard every patient's journey, from anesthesia to recovery.
We do this by developing innovative algorithm-powered monitoring solutions that meet a clinical and digital paradigm shift. Senzime’s shares are listed on Nasdaq Stockholm Main Market (SEZI), cross traded in the US on OTCQX (SNZZF), and backed by strong institutional long-term owners.
Senzime is a leading global medical device company headquartered in Uppsala, Sweden. The company develops, manufactures, and markets a portfolio of innovative patient monitoring solutions to eliminate complications and to help drive patient safety. The target market exceeds 100 million patients a year that undergo surgery and are in postoperative care.
The business model is based on patient monitors and recurring sales of proprietary disposable sensors. Senzime's target market includes more than 15,000 hospitals and 160,000 operating rooms.
Senzime operates globally via sales teams in US and Germany, as well as through license and distribution partnerships in 30+ countries. Senzime’s long-term goal is to be market leader in each of its niches and addressed markets.
The TetraGraph system is used during surgery to accurately monitor a patient’s level of neuromuscular blockade. This helps anaesthesiologists to secure the right dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own.
The TetraGraph system is based on 40 years of scientific research and clinical care under the leadership of Professor Sorin J. Brull of Mayo Clinic and Yale in the United States, and through collaborations with leading international academic centers.
Over USD 50 million has been invested in the development of the TetraGraph system, now powered by its fifth-generation electromyography (EMG) algorithm, strong IP protection and proprietary know-how. Since its market introduction in 2019, TetraGraph has been used on over 150,000 patients at hundreds of leading hospitals across the globe.
ExSpiron is the first and only non-invasive system for continuous monitoring of minute ventilation (the amount of air breathed in a minute) for early detection of respiratory changes typically after surgery, in intensive care and on the general care floor.
The ExSpiron system is based on extensive scientific and clinical scientific research under the leadership of Dr. Jenny Freeman, a Boston-based cardiothoracic surgeon. Over USD 35 million has been invested in the development of the ExSpiron system. ExSpiron is validated on over 6 000 patients with 35+ peer-reviewed publications and protected by 14 patent families.
In late 2022, the two major anesthesiology societies globally (ASA – American Society of Anesthesiologists and ESAIC – European Society of Anaesthesiology and Intensive Care) published guidelines with clinical recommendations encouraging healthcare systems to introduce quantitative neuromuscular monitoring (same technology that Senzime offers) in all places where patients undergo anesthesia and receive neuromuscular blocking drugs.
The new guidelines confirm that there is strong evidence that complications are underestimated, and that many patients are awakened while still exhibiting effects of neuromuscular blocking drugs. This leads to residual neuromuscular weakness for many patients with postoperative pulmonary complications, unpleasant recall, longer hospital stays and delayed return to daily activities as results.
Senzime’s solutions are driven by clinical innovation to meet guidelines and practice recommendations. TetraGraph is the first portable EMG-powered monitor on the market that is clinically validated, and that meets the ASA and ESA guidelines.
Senzime Board of Directors is a global team of experts in business development, clinical research and life science development.
Senzime management is a team of people with extensive global experience in the field of medical devices, healthcare and life science.